New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to ...

Emily Powell-Heaton was eating dinner with a friend when she got a message from Ben Stiller. She tells TODAY.com that her ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

An unassuming painkiller that most people have in their cupboard could help prevent the spread of cancer. Experts might have ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...